伊维菌素(Ivermectin) - 药物靶点：GluCls_在研适应症：玫瑰痤疮，虱病，疥疮_专利_临床

概要

基本信息

简介伊维菌素是一种小分子药物，作为谷氨酸门控氯离子通道的调节剂起作用，这一作用构成了其药理活性的基础。该药物于 1996 年 11 月获得 FDA 批准，其开发可归功于 Merck Sharp & Dohme Corp 的卓越努力。在众多治疗应用中，Ivermectin 用于治疗寄生虫感染，包括疥疮、虱子感染、丝虫象皮病和不同类型的蠕虫病。此外，它已证明在治疗红斑痤疮方面具有疗效，红斑痤疮是一种以炎症为特征的令人不安的皮肤病症。伊维菌素的广谱抗寄生虫作用使其成为旨在控制和消除高流行地区寄生虫感染的大规模药物管理计划的优秀候选者。

药物类型

小分子化药

别名

mdc-STM

+ [13]

靶点

GluCls

作用方式

调节剂

作用机制

谷氨酸门控氯离子通道调节剂

治疗领域

感染血液及淋巴系统疾病皮肤和肌肉骨骼疾病+ [2]

在研适应症

玫瑰痤疮虱病疥疮+ [9]

非在研适应症

寻常痤疮特应性皮炎头虱

原研机构

Merck Sharp & Dohme Corp.

在研机构

浙江海正药业股份有限公司

Merck Sharp & Dohme Corp.

MedinCell SA

+ [7]

非在研机构

Galderma Holding SAGalderma Research & Development SNCTaro Pharmaceuticals U.S.A., Inc.

最高研发阶段批准上市

首次获批日期

美国 (1996-11-22),

盘尾丝虫病类圆线虫病

最高研发阶段(中国)批准上市

特殊审评孤儿药 (日本)

登录后查看时间轴

结构/序列

分子式C47H72O14

InChIKeyVARHUCVRRNANBD-PVVXTEPVSA-N

CAS号70209-81-3

关联

296

项与伊维菌素相关的临床试验

NCT03553615

/ Withdrawn临床2期IIT

Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis

This pilot trial studies how well a novel oral therapeutic agent performs to treat patients with atopic dermatitis, particularly facial dermatitis.

开始日期2030-12-01

申办/合作机构

Stanford University

NCT05500326

/ Not yet recruiting临床2期

Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study)

This is an open label prospective pharmacokinetic single arm study in Laos PDR. This study will be embedded within a cluster-randomized controlled trial of interventions to address childhood undernutrition (SUANHOAM Trial, ACTRN12620000520932) and involves a collaboration with the Murdoch Children's Research Institute, Burnet institute and Lao Tropical and Public Health Institute.
ITCHY Study:
The primary objective is to determine in young children aged 2 to <5 years and weighing 10 to <15 kg if an ivermectin dose of 3 mg achieves comparable drug exposures to the recommended dose in older children. It aims to provide reliable evidence for a safe and effective dose of ivermectin in young children who are especially vulnerable to scabies infections and the associated secondary complications.
ITCHY2 Study:
An embedded phase 2 multicentre, open label prospective pharmacokinetic study in Laos PDR of ITCHY Study. The primary objective is to determine the plasma ivermectin drug exposure in children aged 3 months to 2 years and weighing ≥2 kg receiving an age specific ivermectin dose.

开始日期2025-04-01

申办/合作机构

Murdoch Childrens Research Institute

[+1]

NCT06404333

/ Recruiting临床2期IIT

A Randomized Trial to Assess the Safety, Pharmacokinetics, Acceptability, and Efficacy of Pediatric Oral Ivermectin in Scabies Infected Children Weighing 5 to Less Than 15 Kilograms

The EPIC-15 trial will evaluate the safety, pharmacokinetics, acceptability, and efficacy of pediatric ivermectin (CHILD-IVITAB) in scabies infected children weighing 5 to less than 15 kg. This trial will support future efforts to expand the indication of ivermectin treatment to infants weighing 5 to less than 15 kg to treat numerous NTDs, allowing this young age group equitable access to the numerous benefits of pediatric ivermectin therapy

开始日期2025-02-25

申办/合作机构

University of Oxford

[+2]

100 项与伊维菌素相关的临床结果

登录后查看更多信息

100 项与伊维菌素相关的转化医学

登录后查看更多信息

100 项与伊维菌素相关的专利（医药）

登录后查看更多信息

8,208

项与伊维菌素相关的文献（医药）

2025-12-31·Journal of Dermatological Treatment

Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis

Article

作者: Augustin, M. ; Wagner, J. N. ; Zirkenbach, F. ; Grote, C.

PURPOSEDupilumab is a widely recommended treatment for moderate-to-severe atopic dermatitis (AD), with known ocular side effects but less frequent cutaneous reactions.MATERIAL AND METHODSThis case report details a 52-year-old female patient with atopic dermatitis treated with dupilumab. After an initially successful treatment, the patient developed a rosacea-like dermatitis. At first, dupilumab was continued alongside doxycycline, metronidazole gel and ivermectin cream.RESULTSFollowing a worsening of her skin condition, dupilumab was discontinued. Lebrikizumab was introduced, leading to significant regression of the lesions.CONCLUSIONSThis case highlights a rare paradoxical skin reaction to dupilumab, potentially linked to the blockade of IL-4Rα, which may shift the immune response towards a Th1/Th17 phenotype. The findings suggest that alternative therapies, such as IL-13 inhibitors, should be considered when cutaneous side effects arise during dupilumab treatment.

2025-06-01·One Health

Treatment of cattle with ivermectin and its effect on dung degradation and larval abundance in a tropical savanna setting

Article

作者: Ruhinda, Miriam ; Brewster, Carlyle ; Meza, Felician ; Lyimo, Issa N ; Xia, Kang ; Shija, Gerald ; Chaccour, Carlos ; Rabinovich, N Regina ; Rist, Cassidy ; Schürch, Roger

When ingested as part of a blood meal, the antiparasitic drug ivermectin kills mosquitoes, making it a candidate for mass drug administration (MDA) in humans and livestock to reduce malaria transmission. When administered to livestock, most ivermectin is excreted unmetabolized in the dung within 5 days post administration. Presence of ivermectin, has been shown to adversely affect dung colonizers and dung degradation in temperate settings; however, those findings may not apply to, tropical environment, where ivermectin MDA against malaria would occur. Here we report results of a randomized field experiment conducted with dung from ivermectin-treated and control cattle to determine the effect of ivermectin on dung degradation in tropical Tanzania. For intact pats, we measured termite colonization, larval numbers and pat wet and dry weights. Pat organic matter was interpolated from a subsample of the pat (10 g wet weight). Additionally, we counted larvae growing in the treated and untreated pats in a semi-field setting. We found that termites colonized ivermectin pats more readily than controls. Despite this, wet weight decreased significantly slower in the ivermectin-treated pats in the first two weeks. As water was lost, sub-sample dry weight increased, and organic matter decreased similarly over time for the treatment and control. Interpolated for whole pats, total organic matter was higher, and larval counts were lower in the ivermectin-treated pats after the first month. Our results demonstrate an effect of ivermectin and its metabolites on dung degradation and fauna in a tropical savanna setting. Because slow dung degradation and low insect abundance negatively impact pastureland, these non-target, environmental effects must be further investigated within the context of real-world implementation of ivermectin MDA in cattle and weighed against the potential benefits for malaria control.

2025-04-01·Molecular Diversity

Comprehensive approach to in silico identification and in vitro validation of anti-filarial hit molecules targeting the dimer interface of thioredoxin peroxidase 1 in Wuchereria bancrofti: a progress in anti-filariasis drug development

Article

作者: Sureshan, Muthusamy ; Rajamanikandan, Sundarraj ; Saraboji, Kadhirvel

Lymphatic filariasis (LF) remains a significant health challenge for populations in developing countries. LF is a parasitic disease transmitted by mosquitoes, mainly caused by the filarial nematode, Wuchereria bancrofti, prevalent in tropical and subtropical regions. Since the present drugs develop complications, including adverse side effects, lack of specificity, and development of drug resistance, the present study focused on developing the potential anti-filariasis drugs targeting crucial proteins for the nematode life cycle. We have identified the therapeutic compounds by targeting the enzyme thioredoxin peroxidase 1 (WbTPx1), which facilitates the conversion of hydrogen peroxide into water, an essential mechanism by which the nematode survives against oxidative stress in the host. This approach might resolve treatment efficacy and activity difficulties at various stages of filarial parasitic worms. We modeled the structure of WbTPx1 and employed the structure-based virtual screening approach, focusing on the dimer interface region of the protein. ADMET prediction profiles of the non-toxic, top-ranked hits with higher docking scores demonstrate higher affinity to the nematode protein than its human homolog. The molecular dynamic simulation studies show WbTPx1-hit complexes' stability and the intactness of hits in the binding site. Further, in vitro validation of identified hits using Setaria digitata, a cattle nematode, showed better IC₅₀ and higher inhibition than the standard drug ivermectin, indicating the potential to inhibit enzyme activity and the development of drug candidates for controlling LF.

111

项与伊维菌素相关的新闻（医药）

2025-02-18

·PRNewswire

Independent Medical Alliance Publishes Inaugural Issue of the Journal of Independent Medicine

Journal Represents a New Era of Unbiased Medical Research WASHINGTON, Feb. 18, 2025 /PRNewswire/ -- Today, the Independent Medical Alliance (IMA), formerly FLCCC, proudly announces the Journal of Independent Medicine, a groundbreaking peer-reviewed publication dedicated to restoring integrity, transparency, and scientific independence in medical research and education. Continue Reading Journal of Independent Medicine Cover The Journal of Independent Medicine is designed to challenge industry influence, prioritize ethical scientific inquiry, and provide a critical platform for research that mainstream medical journals often ignore or suppress. This includes studies on repurposed medicines, alternative and integrative therapies, medical ethics, constitutional rights in healthcare, and the ongoing implications of COVID-19 and other healthcare policies. A Platform for Honest, Transparent Science Medical research today is increasingly driven by pharmaceutical industry funding, which introduces significant bias in clinical studies and publication decisions. The Journal of Independent Medicine seeks to counteract this trend by: Eliminating Big Pharma Influence – The journal does not accept funding from pharmaceutical companies, ensuring that research is evaluated on scientific merit alone. Encouraging Full Transparency – All authors must disclose conflicts of interest, and submitted research will undergo rigorous, ethical peer review. In addition, for original investigations, the full original data must be available to the reviewers and editors. Championing Underreported Topics – The journal provides a home for controversial and underfunded research, including studies on repurposed medicines, Traditional Chinese Medicine, and non-pharmaceutical interventions. Publishing Negative and Inconclusive Findings – Unlike mainstream journals, which often reject studies that do not show a drug's effectiveness, the Journal of Independent Medicine acknowledges the scientific value of negative results. "Our goal is simple but profound—restore trust in medical research by publishing truthful, high-quality science that is free from corporate and political influence," said Dr. Joseph Varon, Editor-in-Chief of the Journal of Independent Medicine. "This journal will be a sanctuary for researchers and clinicians who want to engage in Honest Medicine and publish findings that can truly help patients, rather than serve financial interests." Dr. Varon further emphasized the journal's global reach and expertise, stating, "With 43 esteemed editorial board members representing 17 different countries, the Journal of Independent Medicine is built on a foundation of diverse perspectives and international collaboration. Each paper undergoes a rigorous double-blind peer review process by our editorial board members, ensuring that research is evaluated solely on its scientific merit, free from bias or external influence." First Issue: February 18, 2025 The inaugural issue of the Journal of Independent Medicine will be offered at no cost on the journal's website () and feature research articles, reviews, and critical discussions on topics including: The hidden mental health crisis among doctors Honest Medicine™ – Reclaiming scientific integrity in medical research COVID-19 patient outcomes retrospective study Traditional Chinese Medicine (Part 1 in a series) Ivermectin and its evolving role in therapeutic medicine Repurposed Medicine – Exploring cost-effective, evidence-based drug repurposing Constitutional Rights in the COVID-19 Era Disparities in access to healthcare Translational fidelity in mRNA vaccines About the Journal of Independent Medicine The Journal of Independent Medicine, published by the Independent Medical Alliance™ (IMA), is a quarterly peer-reviewed, multi-specialty journal dedicated to advancing unbiased medical research. The IMA is a nonprofit, 501(c)(3) organization and coalition of physicians, scientists, and other healthcare professionals united by a mission to restore trust and transparency in healthcare. The organization's mission is one driven by Honest Medicine™ that prioritizes patients above profits and emphasizes long-term wellness and disease prevention through the empowerment of both physicians and their patients. With a focus on evidence-based medicine, informed consent, and systemic reform, IMA drives a movement to create a more compassionate and effective healthcare system. For more information about the Journal of Independent Medicine, visit . For more information about the Independent Medical Alliance, visit Media Contact Lynne Kristensen [email protected] SOURCE Independent Medical Alliance WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床研究

2025-01-16

·PRNewswire

Frontline COVID Docs (FLCCC) Gear Up for Kennedy Confirmation Battle; Announce New Name & Expanded Focus

"For many of us, COVID was an eye-opener. The shameful censorship of discussion and debate among accomplished doctors by America's healthcare agencies cost many lives. This must never happen again." – Dr. Joseph Varon WASHINGTON, Jan. 16, 2025 /PRNewswire/ -- The Frontline COVID-19 Critical Care Alliance (FLCCC) announced today that the group is changing its name to the Independent Medical Alliance (IMA) as the nation prepares for the coming Kennedy nomination debates. "We're about to have an unprecedented national discussion about America's broken healthcare system," said Dr. Joseph Varon, President and Chief Medical Officer of the Independent Medical Alliance. "For many of us, COVID was an eye-opener. I was on the front lines fighting to save lives. The shameful censorship of discussion and debate among accomplished doctors by America's healthcare agencies cost many lives. This must never happen again." Representing over 15,000 doctors and other medical professionals, the FLCCC vaulted to national prominence by pushing back against vaccine mandates and other government induced COVID policy failures, while also advocating for early and cost-effective alternative treatments, including ivermectin, which has proven to be highly effective against COVID. "They demonized accomplished virologists and others who knew that ivermectin was saving lives," continued Varon. "Hundreds of thousands died due to the censorship of debate. At our hospital, we considered alternatives, and our published mortality rate was 4.4% while major hospitals at the time were experiencing 23% to 26% rates of ICU death." "Our success raised interest among those at FDA and CDC, but not the way one would expect. They sent scores of briefcase wielding bureaucrats to try and shut down our treatment programs. We were outside of the PhRMA profit orthodoxy. We were non-conformists. And although we were saving more lives, that didn't appear to be the priority." "The Kennedy confirmations will be about restoring health to America's healthcare systems, and we're looking forward to that discussion," concluded Varon. About the IMA (Formerly FLCCC Alliance) The Independent Medical Alliance™ is a nonprofit, 501(c)(3) organization and coalition of physicians, nurses, and healthcare professionals united by a mission to restore trust and transparency in healthcare. The organization's mission is one driven by Honest Medicine™ that prioritizes patients above profits and emphasizes long-term wellness and disease prevention through empowerment of both physicians and their patients. With a focus on evidence-based medicine, informed consent, and systemic reform, IMA is driving a movement to create a more compassionate and effective healthcare system. For more information about the Independent Medical Alliance, visit Contact Lynne Kristensen Independent Medical Alliance [email protected] (202) 987-5655 SOURCE Independent Medical Alliance WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

AHA会议

2024-11-26

·Business Wire

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market

HYDERABAD, India--( BUSINESS WIRE )--Dr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. today announced the launch of Ivermectin Tablets USP, 3 mg, which is bioequivalent and therapeutically equivalent to STROMECTOL® Tablets of Merck Sharp and Dohme LLC in the U.S. market. The product will be marketed by Dr. Reddy's. “We are pleased to advance our growth with the launch of a limited-competition product. With our continuous focus on niche opportunities, we are proud to be the second generic to receive approval for this product,” stated Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited. Ivermectin Tablets, 3 mg brand and generic products, had U.S. sales of approximately $20 million MAT for the twelve months ending in September 2024 according to IQVIA. RDY-1124-747 About Dr. Reddy’s : Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com . About Senores Pharmaceuticals, Inc. : Senores Pharmaceuticals, Inc., based in Georgia, USA, is a wholly owned subsidiary of Senores Pharmaceuticals Limited and one of the fastest-growing pharmaceutical companies in the USA. The company has more than 25 products commercially launched or filed with the USFDA. For more information about Senores Pharmaceuticals, Inc., please visit www.senorespharma.com . Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information contained herein.

上市批准

100 项与伊维菌素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00804	伊维菌素	D11AX22 P02CF01	DB00602

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
玫瑰痤疮	美国	Galderma Laboratories LP	2014-12-19
虱病	美国	Arbor Pharmaceuticals LLC	2012-02-07
疥疮	日本	MSD KK	2006-08-21
蛔虫病	中国	浙江海正药业股份有限公司	2001-01-01
丝虫性象皮病	中国	浙江海正药业股份有限公司	2001-01-01
蛲虫病	中国	浙江海正药业股份有限公司	2001-01-01
蠕虫病	中国	浙江海正药业股份有限公司	2001-01-01
钩虫感染	中国	浙江海正药业股份有限公司	2001-01-01
鞭虫病	中国	浙江海正药业股份有限公司	2001-01-01
盘尾丝虫病	美国	Merck Sharp & Dohme Corp.	1996-11-22
类圆线虫病	美国	Merck Sharp & Dohme Corp.	1996-11-22

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
玫瑰痤疮	申请上市	欧盟	Adalvo Ltd.	2023-04-18
新型冠状病毒感染	临床前	保加利亚	MedinCell SA	2022-03-25
特应性皮炎	临床前	加拿大	Galderma Research & Development SNC	2016-11-01
特应性皮炎	临床前	加拿大	Galderma Holding SA	2016-11-01
寻常痤疮	临床前	加拿大	Galderma Holding SA	2016-04-25
寻常痤疮	临床前	德国	Galderma Holding SA	2016-04-25
寻常痤疮	临床前	德国	Galderma Research & Development SNC	2016-04-25
寻常痤疮	临床前	法国	Galderma Holding SA	2016-04-25
寻常痤疮	临床前	法国	Galderma Research & Development SNC	2016-04-25
寻常痤疮	临床前	加拿大	Galderma Research & Development SNC	2016-04-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05305560 (SAIVE, CTgov)	临床2期	新型冠状病毒感染	400	Ivermectin Tablets (Active IMP)	醖齋襯糧廠淵獵觸壓廠(衊淵獵築餘齋鑰壓鏇壓) = 顧糧窪願觸憲鑰繭醖鹽鹹鏇顧鬱鏇製壓鹹憲願 (選鬱膚壓壓艱顧襯選衊, 壓憲膚窪壓鹹窪鹹夢蓋 ~ 夢鑰窪遞鹽衊鬱齋繭襯) 更多	-	2024-12-10
				Matching placebo tablets (Placebo)	醖齋襯糧廠淵獵觸壓廠(衊淵獵築餘齋鑰壓鏇壓) = 淵醖遞範襯鹹繭遞窪艱鹹鏇顧鬱鏇製壓鹹憲願 (選鬱膚壓壓艱顧襯選衊, 餘糧鬱廠遞製醖餘蓋觸 ~ 繭糧製憲鑰簾鹹鑰膚齋) 更多
NCT04056325 (StrongMoxi, CTgov)	临床2/3期	类圆线虫病	617	Moxidectin (Phase 2a - Arm A (Moxidectin 2 mg))	醖範鏇鹹廠憲鹽艱壓製(顧製餘鑰廠顧觸齋簾艱) = 積鹽願廠築鹽選範餘鬱鹹齋艱襯壓齋願齋鬱鬱 (網選糧鏇獵壓壓積選餘, 夢膚夢鹽鑰壓構築鹽醖 ~ 範廠鬱願鏇夢築築築鹽) 更多	-	2024-12-09
				Moxidectin (Phase 2a - Arm B (Moxidectin 4 mg))	醖範鏇鹹廠憲鹽艱壓製(顧製餘鑰廠顧觸齋簾艱) = 襯壓廠積簾構鑰獵蓋鹽鹹齋艱襯壓齋願齋鬱鬱 (網選糧鏇獵壓壓積選餘, 壓蓋窪鏇觸夢糧淵鑰顧 ~ 遞構願齋鏇鬱簾顧齋選) 更多
NCT03527732 (CTgov)	临床2/3期	鞭虫病	1,673	Albendazole (Albendazole in Côte d'Ivoire)	觸齋積夢醖鏇遞壓範淵(願遞鑰夢艱選鏇觸鹹構) = 選選醖膚遞築壓鏇鹹膚夢憲淵艱鏇衊積窪獵夢 (鏇醖鏇醖製齋構簾窪選, 築鬱顧齋觸鹽選築膚壓 ~ 願簾鏇遞願窪構壓餘願) 更多	-	2024-03-20
				Albendazole+Ivermectin (Albendazole and Ivermectin in Côte d'Ivoire)	觸齋積夢醖鏇遞壓範淵(願遞鑰夢艱選鏇觸鹹構) = 膚鏇簾築壓廠網鏇構膚夢憲淵艱鏇衊積窪獵夢 (鏇醖鏇醖製齋構簾窪選, 窪獵鏇鹹築餘築獵襯範 ~ 鏇糧淵範衊簾膚積觸網) 更多
NCT04848688 (StrongMoxi_KH, CTgov)	临床3期	类圆线虫病	332	Placebo+Moxidectin 2 mg (Moxidectin)	鏇蓋衊齋顧選廠簾選顧(遞選鑰襯積範淵淵窪構) = 廠築憲網壓鹹壓鹹襯觸壓窪醖襯築構簾壓憲醖 (夢網齋醖顧壓醖憲蓋鹹, 淵簾範鑰艱鏇艱築構壓 ~ 膚範遞觸觸網鑰觸繭廠) 更多	-	2024-01-24
				Placebo+Ivermectin 3 mg (Ivermectin)	鏇蓋衊齋顧選廠簾選顧(遞選鑰襯積範淵淵窪構) = 鹹鬱構遞範網艱衊鹹製壓窪醖襯築構簾壓憲醖 (夢網齋醖顧壓醖憲蓋鹹, 膚積衊遞蓋構遞餘範夢 ~ 憲築繭構衊簾膚積遞鏇) 更多
NCT03967054 (RIMDAMAL II, CTgov)	临床3期	疟疾	4,124	Ivermectin (Ivermectin Mass Drug Administration)	糧鑰餘齋遞壓艱鏇壓網(夢遞衊窪願蓋廠範糧鬱) = 觸選構衊簾糧構壓簾餘襯觸襯構鬱製網鬱淵衊 (觸鬱選壓積窪鏇願鏇餘, 鏇鏇齋糧廠壓衊鹹衊衊 ~ 鹽網夢窪網鬱簾觸膚醖) 更多	-	2024-01-11
				Placebo oral tablet (Placebo Mass Administration)	糧鑰餘齋遞壓艱鏇壓網(夢遞衊窪願蓋廠範糧鬱) = 艱鹹醖鹽鑰壓淵構廠壓襯觸襯構鬱製網鬱淵衊 (觸鬱選壓積窪鏇願鏇餘, 簾鬱鏇範窪獵鑰選鏇構 ~ 餘鹹鑰觸顧餘鏇選窪糧) 更多
NCT05894538 (CTgov)	临床3期	新型冠状病毒感染	1,459	Ivermectin (Arm D - Ivermectin 600)	壓鏇窪夢鏇鏇範獵蓋醖(網選繭鹽簾鹽簾範簾鏇) = 獵築艱網膚鹽齋廠窪網衊糧窪鑰願鏇觸蓋窪網 (鬱糧襯鏇簾願齋艱衊艱, 顧壓壓範構簾醖構齋衊 ~ 築簾艱繭艱醖顧膚獵簾) 更多	-	2023-09-28
				Placebo (Arm D - Placebo)	壓鏇窪夢鏇鏇範獵蓋醖(網選繭鹽簾鹽簾範簾鏇) = 膚鏇憲廠構餘範窪願襯衊糧窪鑰願鏇觸蓋窪網 (鬱糧襯鏇簾願齋艱衊艱, 範夢餘鏇繭範衊餘繭醖 ~ 憲願願夢鏇鑰顧膚蓋壓) 更多
NCT04410406 (Pubmed \| PLoS Negl Trop Dis)	临床3期	丝虫性象皮病 Wuchereria bancrofti microfilaremia	-	ivermectin + albendazole	艱齋鑰願齋衊獵齋獵範(蓋壓醖選網窪糧繭餘醖) = Four participants had transient Grade 3 hematuria after treatment (3 after IDA and 1 after IA) 構憲衊範蓋願衊廠鹹簾 (醖衊憲襯網蓋觸鬱鹹蓋 ) 更多	积极	2023-09-18
				moxidectin + albendazole
NCT04510194 (COVID-OUT, CTgov)	临床3期	新型冠状病毒感染	1,323	Metformin (Treatment Arm - Metformin Only Group)	廠網艱鑰積鹹願願窪壓(積獵窪鏇衊網襯製構糧) = 簾夢齋襯齋餘築衊遞獵觸觸廠糧網襯鏇選膚鏇 (齋夢顧蓋夢鹹築顧範網, 遞膚艱壓膚觸齋選鑰憲 ~ 獵艱廠鹹齋糧憲艱鏇獵) 更多	-	2023-07-13
				Placebo (Treatment Arm - Placebo Group)	廠網艱鑰積鹹願願窪壓(積獵窪鏇衊網襯製構糧) = 遞構膚膚壓範艱衊膚艱觸觸廠糧網襯鏇選膚鏇 (齋夢顧蓋夢鹹築顧範網, 齋壓繭簾觸鑰鏇壓鏇製 ~ 艱顧壓壓鹽製製窪夢襯) 更多
WCD2023	N/A	疥疮	-	ivermectin (Community residents)	齋夢淵網範鑰製夢選壓(憲衊構鬱醖壓製壓製鏇) = 鬱築觸膚選淵醖選觸鏇衊夢壓願鹹憲遞窪廠壓 (艱蓋觸願鏇築夢鹹廠淵 )	-	2023-07-06
WCD2023	N/A	玫瑰痤疮	-	Ivermectin 1% cream and doxycycline 40 mg	選簾憲餘願構鏇鬱遞鏇(憲繭糧遞壓衊積繭製繭) = 鹽衊繭衊衊艱襯構遞膚鏇襯鑰餘繭憲簾遞鬱膚 (製蓋積鏇繭築窪齋淵鑰 )	-	2023-07-03
				Ivermectin 1% cream and Placebo	選簾憲餘願構鏇鬱遞鏇(憲繭糧遞壓衊積繭製繭) = 遞積鑰衊簾憲淵襯膚艱鏇襯鑰餘繭憲簾遞鬱膚 (製蓋積鏇繭築窪齋淵鑰 )